J&J maintains expansion into device sector

Johnson & Johnson Vision Care has acquired ophthalmic medical device maker Tearscience for an undisclosed sum.

North Carolina-based Tearscience produces devices focused on treating meibomian gland dysfunction and recently won FDA clearance for its practice-based treatments.

‘Dry eye is a significant unmet health need globally and meibomian gland dysfunction is the cause for more than 60% of people living with this condition,’ said J&J Vision Care companies group chair Ashley McEvoy.

‘The innovative portfolio from Tearscience positively impacts the lives of patients around the world suffering from this chronic condition. These solutions, coupled with our existing contact lens and surgical portfolio, will allow us to help more patients with their vision needs, throughout their lifetime.’